These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 27463058)

  • 1. Prioritizing Hits with Appropriate Trade-Offs Between HIV-1 Reverse Transcriptase Inhibitory Efficacy and MT4 Blood Cells Toxicity Through Desirability-Based Multiobjective Optimization and Ranking.
    Cruz-Monteagudo M; PhamThe H; Cordeiro MN; Borges F
    Mol Inform; 2010 Apr; 29(4):303-21. PubMed ID: 27463058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desirability-based methods of multiobjective optimization and ranking for global QSAR studies. Filtering safe and potent drug candidates from combinatorial libraries.
    Cruz-Monteagudo M; Borges F; Cordeiro MN; Cagide Fajin JL; Morell C; Ruiz RM; Cañizares-Carmenate Y; Dominguez ER
    J Comb Chem; 2008; 10(6):897-913. PubMed ID: 18855460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design.
    Zhan P; Chen X; Li D; Fang Z; De Clercq E; Liu X
    Med Res Rev; 2013 Jun; 33 Suppl 1():E1-72. PubMed ID: 21523792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The application of structural optimization strategies in drug design of HIV NNRTIs].
    Wang L; Zhan P; Liu XY
    Yao Xue Xue Bao; 2012 Nov; 47(11):1409-22. PubMed ID: 23387070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
    Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
    HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for NNRTIs with slow dissociation and high affinity for a panel of HIV-1 RT variants.
    Elinder M; Nordström H; Geitmann M; Hämäläinen M; Vrang L; Oberg B; Danielson UH
    J Biomol Screen; 2009 Apr; 14(4):395-403. PubMed ID: 19403922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
    Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
    ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014).
    Li X; Zhang L; Tian Y; Song Y; Zhan P; Liu X
    Expert Opin Ther Pat; 2014 Nov; 24(11):1199-227. PubMed ID: 25313716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010).
    Zhan P; Liu X
    Expert Opin Ther Pat; 2011 May; 21(5):717-96. PubMed ID: 21457080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SeleX-CS: a new consensus scoring algorithm for hit discovery and lead optimization.
    Bar-Haim S; Aharon A; Ben-Moshe T; Marantz Y; Senderowitz H
    J Chem Inf Model; 2009 Mar; 49(3):623-33. PubMed ID: 19231809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS?
    De Clercq E; Balzarini J
    Farmaco; 1995 Nov; 50(11):735-47. PubMed ID: 8593170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidimensional drug design: simultaneous analysis of binding and relative efficacy profiles of N(6)-substituted-4'-thioadenosines A3 adenosine receptor agonists.
    Cruz-Monteagudo M; Cordeiro MN; Teijeira M; González MP; Borges F
    Chem Biol Drug Des; 2010 Jun; 75(6):607-18. PubMed ID: 20408851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.
    Jayaweera D; Dilanchian P
    Expert Opin Pharmacother; 2012 Dec; 13(18):2601-12. PubMed ID: 23176566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
    Andries K; Azijn H; Thielemans T; Ludovici D; Kukla M; Heeres J; Janssen P; De Corte B; Vingerhoets J; Pauwels R; de Béthune MP
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4680-6. PubMed ID: 15561844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desirability-based multiobjective optimization for global QSAR studies: application to the design of novel NSAIDs with improved analgesic, antiinflammatory, and ulcerogenic profiles.
    Cruz-Monteagudo M; Borges F; Cordeiro MN
    J Comput Chem; 2008 Nov; 29(14):2445-59. PubMed ID: 18452123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.
    Adams J; Patel N; Mankaryous N; Tadros M; Miller CD
    Ann Pharmacother; 2010 Jan; 44(1):157-65. PubMed ID: 19996323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.